171 related articles for article (PubMed ID: 34502195)
1. (20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2.
Wang YS; Chen C; Zhang SY; Li Y; Jin YH
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502195
[TBL] [Abstract][Full Text] [Related]
2. The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity.
Wang YS; Lin Y; Li H; Li Y; Song Z; Jin YH
Sci Rep; 2017 Sep; 7(1):12408. PubMed ID: 28963461
[TBL] [Abstract][Full Text] [Related]
3. (20S) Ginsenoside Rh2 Exerts Its Anti-Tumor Effect by Disrupting the HSP90A-Cdc37 System in Human Liver Cancer Cells.
Chen C; Wang YS; Zhang ET; Li GA; Liu WY; Li Y; Jin YH
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884975
[TBL] [Abstract][Full Text] [Related]
4. (20S)G-Rh2 Inhibits NF-κB Regulated Epithelial-Mesenchymal Transition by Targeting Annexin A2.
Wang YS; Li H; Li Y; Zhang S; Jin YH
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32244350
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.
Qiang SQ; Qin GC; Jing L; Qiang FZ; Mei QH; Long CD
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2529-2539. PubMed ID: 34452568
[TBL] [Abstract][Full Text] [Related]
6. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β‑catenin signaling pathway.
Xu L; Li J; Hou N; Han F; Sun X; Li Q
Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):688-696. PubMed ID: 38584523
[TBL] [Abstract][Full Text] [Related]
7. CD147 regulates cancer migration via direct interaction with Annexin A2 and DOCK3-β-catenin-WAVE2 signaling.
Cui HY; Wang SJ; Miao JY; Fu ZG; Feng F; Wu J; Yang XM; Chen ZN; Jiang JL
Oncotarget; 2016 Feb; 7(5):5613-29. PubMed ID: 26716413
[TBL] [Abstract][Full Text] [Related]
8. Pseudo-ginsenoside Rh2 Induces Protective Autophagy in Hepatocellular Carcinoma HepG2 Cells.
Zhang F; Xu H; Xia R; Yu P; Li Y; Yu X; Sui D
Recent Pat Anticancer Drug Discov; 2021; 16(4):521-532. PubMed ID: 34109916
[TBL] [Abstract][Full Text] [Related]
9. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O
BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980
[TBL] [Abstract][Full Text] [Related]
10. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
11. 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol negatively regulates activation of STAT3 and ERK pathways and exhibits anti-cancer effects in HepG2 cells.
Ai HH; Zhou ZL; Sun LG; Yang MT; Li W; Yu CL; Song ZB; Huang YX; Wu Y; Liu L; Yang XG; Zhao YQ; Bao YL; Li YX
Apoptosis; 2017 Nov; 22(11):1404-1418. PubMed ID: 28864870
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice.
Lv Q; Rong N; Liu LJ; Xu XL; Liu JT; Jin FX; Wang CM
Planta Med; 2016 May; 82(8):705-11. PubMed ID: 27163230
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells.
Han S; Jeong AJ; Yang H; Bin Kang K; Lee H; Yi EH; Kim BH; Cho CH; Chung JW; Sung SH; Ye SK
J Ethnopharmacol; 2016 Dec; 194():83-90. PubMed ID: 27566200
[TBL] [Abstract][Full Text] [Related]
14. EH-42: A Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells through Suppressing STAT3 Signaling Pathway.
Gong QZ; Xiao D; Gong GY; Xu J; Wen XD; Feng F; Qu W
Curr Cancer Drug Targets; 2019; 19(7):583-593. PubMed ID: 30585547
[TBL] [Abstract][Full Text] [Related]
15. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
Li Q; Li B; Dong C; Wang Y; Li Q
Eur J Pharmacol; 2017 Nov; 815():173-180. PubMed ID: 28928088
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
17. Protopanaxadiol inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by targeting STAT3 pathway.
Yang L; Zhang XY; Li K; Li AP; Yang WD; Yang R; Wang P; Zhao ZH; Cui F; Qin Y; Yang JH; Tao HL; Sun T; Chen S; Yu PH; Liu HJ; Yang C
Cell Death Dis; 2019 Aug; 10(9):630. PubMed ID: 31431619
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling.
Liu P; Atkinson SJ; Akbareian SE; Zhou Z; Munsterberg A; Robinson SD; Bao Y
Sci Rep; 2017 Oct; 7(1):12651. PubMed ID: 28978924
[TBL] [Abstract][Full Text] [Related]
19. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
20. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
